反应详情

2-Chloro-9-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-6-(2-propylimidazol-1-yl)purine (0.615 g, 1 mmol) was treated with a solution of BnI in CH3CN (0.3 M, 40 mL, 12 mmol) by method 3 to give 3-benzyl-1-{2-chloro-9-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]purin-6-yl}-2-propylimidazolium iodide (0.83 g, crude): 1H NMR (500 MHz, CDCl3) δ 8.94 (s, 1H), 8.49 (s, 1H), 8.00 (d, J=8.5 Hz, 2H), 7.88 (d, J=8.0 Hz, 2H), 7.81 (s, 1H), 7.46-7.50 (m, 5H), 7.32 (d, J=8.0 Hz, 2H), 7.25 (d, J=8.0 Hz, 2H), 6.67 (t, J=7.3 Hz, 1H), 5.75-5.85 (m, 3H), 4.71-4.82 (m, 3H), 3.67-3.74 (m, 2H), 2.99-3.02 (m, 2H), 2.47 (s, 3H), 2.42 (s, 3H), 1.75-1.81 (m, 2H), 1.17 (t, J=7.5 Hz, 3H); HRMS m/z 705.2606 (M+[C39H38ClN6O5=705.2592]).